AB0384 Rheumatic arthritis patients with very high cardiovascular risk: poor results in changes in lifestyle during follow-up

Nonalcoholic fatty liver disease (NAFLD) is defined as the presence of hepatic fat accumulation after ruling out other causes of hepatic steatosis. The aim of the study is to identify the role of statin therapy in dyslipidemic patients with very high cardiovascular risk and NAFLD in achieving low density lipoprotein (LDL) cholesterol targets while also evaluating the changes in liver enzymes levels. This prospective study included 140 patients with NAFLD, hyperlipidemia and elevated cardiovascular risk. Serum lipids were assessed and liver function tests were performed at baseline and at 6 months follow up in 10 mg/ 20 mg daily atorvastatin treatment schedule. The results showed that total cholesterol, LDL cholesterol and triglycerides were significantly reduced at 6 months follow-up, while high density lipoprotein (HDL) cholesterol has not undergone important changes. Statin treatment significantly improved alanine aminotransferase serum levels, whereas aspartate aminotransferase levels were not significantly reduced between baseline and follow-up. Although statin therapy appears to be safe and effective for use in patients with NAFLD, an insufficient treatment is commonly observed in clinical practice, in order to avoid liver damage . NAFLD is not only a major cause of liver related morbidity and mortality, but also an independent cardiovascular risk factor, with cardiovascular mortality being the most important cause of death. Therefore, detecting and modifying risk factors without impairing liver function is desirable.

Download Full-text

Alirocumab effectiveness and rapidity in achieving and maintaining target LDL, HDL cholesterol and triglyceride values in patients at very high cardiovascular risk

European Journal of Preventive Cardiology ◽

10.1093/eurjpc/zwab061.287 ◽

2021 ◽

Vol 28 (Supplement_1) ◽

Author(s):

M Cavarra ◽

E Salerno ◽

G Chiaranda"

Keyword(s):

Cardiovascular Risk ◽

High Risk ◽

Case Studies ◽

Ldl Cholesterol ◽

Hdl Cholesterol ◽

High Cardiovascular Risk ◽

Target Value ◽

Target Values ◽

Very High

Abstract Funding Acknowledgements Type of funding sources: None. Introduction Still too few patients after an acute cardiocerebrovascular event reach C-LDL values recommended by guidelines even in therapy with statins and ezetimibe, thus maintaining a high risk of new cardiovascular episodes. Purpose To evaluate, in a long follow-up, the effectiveness and the rapidity of alirocumab in the attainment and maintenance of LDL-cholesterol target values in patients at very high risk and intolerant to statins. Methods Our case studies consist of 72 patients, 80% males (58) and 20% females (14), with an average age of 61.9. 90.2% of patients were hypertensive. 5.5% had chronic kidney disease (CKD stage III). 65.2% had an ACS and the 34.7% had CeVD. 84.7% of the patients were in therapy only with ezetimibe while 15.3% in association with PUFA N-3. The average value of C-LDL was 169.2 mg/dl. The follow up was 24 months with clinical checks and C-LDL at 3,6,12 and 24 months. The dosage of alirocumab was both 75 and 150 mg Results At 3 months the reduction of C-LDL was 52.24%; at 6 months of 51.18%; at 12 months of 51.36% and at 24 months of 52.47%. The 37 patients who had started with 150 mg, had a very high average C-LDL base, 183.0 mg/dl, and showed a reduction of C-LDL to 3 months of 59.04%, to 6 months of 58.45%, to 12 months of 65.05%, to 24 months of 55.76%. The target value of C-LDL recommended by the ESC guidelines was reached for 42.10% at 3 months; for 52.63% at 6 months; for 63.15% at 12 months and for 73.68% at 24 months. 5.5% of patients with a CKD showed a 73.68% reduction in C-LDL values to 3 months, 65.22% to 6 months, 57.49% to 12 months and 53.95% to 24 months. The follow-up to the Tg study showed a reduction of 3.55% to 3 months, an increase of 8.75% to 6 months, a reduction of 1.65% to 12 months and 7.95% to 24 months. C-HDL values showed an increase of 4.55% at 3 months, 3.69% at 6 months, 10.97% at 12 months and 7.82% at 24 months. Conclusions Our case studies have confirmed the effectiveness of alirocumab in reducing C-LDL values in patients at very high cardiovascular risk and the rapidity in reaching the target value set by guidelines for the management of cardiovascular risk. Our study also confirmed the its effectiveness in increasing the values of C-HDL while it was not possible to confirm the reduction of Tg values. % Alirocumab Efficacy C-LDL TGs C-HDL 3 MONTHS -52,24% -3,55% +4,55% 6 MONTHS -51,18% +8,75% +3,69% 12 MONTHS -51,36% -1,65% +10,97% 24 MONTHS -52,47% -7,95% +7,82% C-LDL: LDL-CHOLESTEROL TGs TRIGLYCERIDES C-HDL: HDL-CHOLESTEROL Abstract Figure. % Alirocumab Efficacy

Download Full-text

The Effects of Preventive Counseling Followed by Remote Support Via Telephone on the Motivation to Change Lifestyle in Patients With High and Very High Cardiovascular Risk

Kardiologiia ◽

10.18087/cardio.2020.5.n1009 ◽

2020 ◽

Vol 60 (5) ◽

pp. 41-46

Author(s):

N. V. Pogosova ◽

A. I. Yusubova ◽

Yu. M. Yufereva ◽

A. K. Ausheva ◽

A. V. Karpova ◽

...

Keyword(s):

Cardiovascular Risk ◽

Lifestyle Modification ◽

Main Group ◽

Control Group ◽

Motivation To Change ◽

High Cardiovascular Risk ◽

Preventive Counseling ◽

Randomized Clinical Study ◽

Very High

Aim To evaluate effectiveness of preventive telephone counseling with a nutritional component and distance support for three months with respect of motivation for lifestyle modification in patients with high and very high cardiovascular risk (CVR).Material and methods This prospective, controlled, randomized clinical study in two parallel groups included patients with high and very high CVR (5–9 % and ≥10 % according to the SCORE scale) who had at least two criteria of metabolic syndrome. Patients were randomized to the main and control groups in a 1:1 ratio with age and gender stratification. The main group received comprehensive preventive counseling with a nutritional component and distant support via telephone once in two weeks for three months (total 6 consultations). Patients of the control group received standard counseling by a health center physician. Patients’ motivation for lifestyle changes was evaluated with a questionnaire at baseline and at 6 and 12 months.Results The study included a total of 100 patients (mean age, 59.85±4.47 years, 80 % females). At baseline, 81 % of patients had high and 19% of patients had very high CVR. Patients of the study groups did not differ in major demographic and clinical characteristics. At 6 month of follow-up, the main group showed a significantly more pronounced positive changes in motivation and healthier lifestyle (50 % in the main group vs. 12% in the control group, р<0.01). At 12 months of follow-up, the number of such patients somewhat decreased to 38%. In this process, a vast majority of patients in the control group (82 %) continued theoretically considering the expediency of lifestyle modification.Conclusions Preventive counseling with nutritional component and further distance support via telephone for three months for patients with high and very high CVR provided increased motivation for healthier lifestyle and positive behavioral changes.

Download Full-text

Factors related to the appearance of major events during follow-up of diabetic patients at very high cardiovascular risk

Atherosclerosis ◽

10.1016/j.atherosclerosis.2016.07.680 ◽

2016 ◽

Vol 252 ◽

pp. e133-e134

Author(s):

M. Crespín Crespín ◽

D. García Fuertes ◽

E. Villanueva Fernández ◽

F.J. Castillo Bernal ◽

A. Rodríguez Cubero ◽

...

Keyword(s):

Cardiovascular Risk ◽

Diabetic Patients ◽

High Cardiovascular Risk ◽

Very High

Download Full-text

Evaluation of cardiotoxicity of chemotherapeutic treatment in breast cancer patients according to a local register

South Russian Journal of Therapeutic Practice ◽

10.21886/2712-8156-2021-2-3-48-55 ◽

2021 ◽

Vol 2 (3) ◽

pp. 48-55

Author(s):

A. K. Subbotin ◽

E. I. Tarlovskaya ◽

A. S. Chichkanova

Keyword(s):

Breast Cancer ◽

Cardiovascular Risk ◽

Cancer Patients ◽

Left Ventricular Ejection ◽

Breast Cancer Patients ◽

Chemotherapy Treatment ◽

High Cardiovascular Risk ◽

Chemotherapeutic Treatment ◽

Very High

objective: assess the risk of cardiotoxicity of chemotherapy in breast cancer patients and prevention options according to the Nizhny Novgorod Local Register, as well as assess the prevalence of cardiovascular risk factors, cardiovascular status and baseline cardioprotective therapy of patients included in the register depending on the stage of chemotherapy treatment. Materials and Methods: a local retrospective-prospective register of breast cancer patients receiving polychemotherapy has been created. According to the retrospective part from November 2018 to February 2020, 150 high or very high cardiovascular risk patients with breast cancer receiving chemotherapy treatment are included in the register. Follow-up continued for 4 or 8 courses depending on the prescribed chemotherapy regimen. Cardiotoxicity of chemotherapy was assessed by echocardiography and troponin I (TnI) levels. Results: the register was dominated by patients of high (82%) and very high cardiovascular risk (18%). There were also no significant differences in therapy composition at the time patients were included in the register. After 4 courses of polychemotherapy (PCT), 28 patients (18.9%) showed objective signs of cardiotoxicity. In 22 patients (14.8%) — signs of early cardiotoxicity (18 patients — an increase in the level of TnI, 4 — the appearance of diastolic dysfunction after PCT). In 4 patients (2.7%) — the appearance of heart failure (HF) symptoms without reducing left ventricular ejection fraction (LVEF) and increasing biochemical markers. In 2 patients (1.3%), the development of symptomatic HF with low LVEF. During the follow-up in the cardiotoxicity group, cardioprotective therapy was prescribed. Against the background of the prescription of cardioprotective therapy, 16 patients (88.8%) showed normalization of the level of TnI, on average by 6 courses of PCT. Conclusions: breast cancer patients receiving polychemotherapy with anthracycline antibiotics included in the regimen have a significant risk of cardiotoxic effect, especially early biochemical cardiotoxicity. Timely prescription of cardioprotective therapy allows correcting early signs of biochemical carditoxicity and continuing chemotherapeutic treatment.

Download Full-text

Cardiovascular events and effectiveness of hypolipidemic therapy in patients with familial hypercholesterolemia and patients of very high cardiovascular risk: 3-year follow-up of the RENAISSANCE Registry

Kardiologicheskii vestnik ◽

10.36396/ms.2020.16.3.004 ◽

2020 ◽

pp. 27-36

Author(s):

У.В. Чубыкина ◽

М.В. Ежов

Keyword(s):

Cardiovascular Risk ◽

Familial Hypercholesterolemia ◽

Cardiovascular Events ◽

Density Lipoprotein ◽

High Cardiovascular Risk ◽

Lipoprotein A ◽

History Of ◽

Male Sex ◽

Very High

Цель. Целью исследования явилась оценка эффективности и приверженности гиполипидемической терапии, частоты развития сердечно<со< судистых осложнений в течение 3<летнего периода наблюдения в рамках регистра РЕНЕССАНС (Регистр пациентов с СГХС и пациентов очень высокого сЕрдечно<Сосудистого риска с недоСтАточной эффективНоСтью проводимой гиполипидемической терапии). Материал и методы. РЕНЕССАНС является открытым национальным наблюдательным исследованием и включает больных с семейной ги< перхолестеринемией (СГХС), а также пациентов очень высокого сердечно<сосудистого риска (ОВССР). Учитывали наличие факторов риска атеросклероза, анамнез сердечно<сосудистых заболеваний, гиполипидемическую терапию. В каждом центре выполняли определение концен< трации: общего холестерина (ОХС), триглицеридов (ТГ), холестерина липопротеидов высокой плотности (ХС ЛВП) в сыворотке крови. Содер< жание холестерина липопротеидов низкой плотности (ХС ЛНП) рассчитывали по формуле Фридвальда. Уровень липопротеида(а) измеряли методом иммуноферментного анализа в некоторых центрах. При оценке частоты конечной точки, включавшей фатальные и нефатальные сердечно<сосудистых осложнения (ССО), проводили анализ Каплана — Майера. Результаты. В регистр включено 1570 (средний возраст 54,0±14,6 лет) пациентов с СГХС и 121 (63,5±10,9 лет) больной с ОВССР. В группе СГХС динамическое наблюдение проведено у 594 пациентов (38%) в течение 23,6±14,6 месяцев, конечная точка зарегистрирована у 9% больных. Мужской пол (относительный риск 2,1; 95% доверительный интервал 1,13–3,66; p<0,01), гипертония (2,8; 1,4–5,2; p<0,01), ишеми< ческая болезнь сердца (6,8; 3,5–13,2; p<0,0001), отягощенный анамнез по сердечно<сосудистым заболеваниям (ССЗ) (2,1; 1,1–3,9; p<0,05) и концентрация липопротеида(а) ≥ 30 мг/дл (2,8; 1,1–7,7; p<0,05) явились предикторами развития ССО. В группе СГХС отмечено снижение уровня ОХС от исходного на 19%, ХС ЛНП на 25% (р<0,001 для обоих), целевых значений ХС ЛНП достигли 2% больных. В группе ОВССР динамическое наблюдение проведено у 72 (60%) пациентов в течение 19,7±5,8 месяцев. Ни один больной не достиг целевого уровня ХС ЛНП менее 1,4 ммоль/л. Заключение. Трехлетнее наблюдение за участниками регистра РЕНЕССАНС демонстрирует усиление приверженности гиполипидемической терапии. С увеличением риска развития сердечно<сосудистых осложнений при СГХС ассоциированы мужской пол, наличие гипертонии, ише< мической болезни сердца, отягощенного анамнеза по ССЗ и высокий уровень липопротеида(а). The aim of the study was to evaluate the effectiveness and adherence to hypolipidemic therapy, the frequency of cardiovascular events (CVE) during the 3!year follow!up in the RENAISSANCE registry (Registry of patients with familial hypercholesterolemia and very high cardiovascular risk with insufficient effect of hypolipidemic therapy). Methods. The RENAISSANCE registry is an open, national, observational study and includes patients with familial hypercholesterolemia (FH), as well as patients of very high cardiovascular risk (VHR). We took into consideration atherosclerosis risk factors and history of cardiovascular diseases (CVD), adherence to hypolipidemic therapy. Concentrations of total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL!C) were measured in blood serum in all centers. Low density lipoprotein cholesterol (LDL!C) level was defined according to Friedewald formula. The concentration of lipoprotein(a) was measured by enzyme!linked immunosorbent assay in serum in some centers. Kaplan!Mayer analysis was performed to assess the frequency of fatal and nonfatal CVE. Results. The Registry consisted of 1570 (mean age 54.0±14.6 years) FH patients and 121 (63.5±10.9 years) VHR patients. Data of 594 patients (38%) who had follow!up visits were obtained in FH patients, follow!up duration 23.6±14.6 months, 54 (9%) patients experienced CVE. Male sex (hazard ratio 2.1; 95% confidence interval 1.13!3.66, p<0.01), hypertension (2.8;1.4–5.2; p<0.01), ischemic heart disease (6.8;3.5!13.2; p<0.0001), family history of CVD (2.1;1.1–3.9, p<0.05) and lipoprotein(a) level ≥30 mg/dl (2.8;1.1–7.7; p<0.05) were predictors of CVE. In FH patients the level of TC decreased by 19%, LDL!C by 25% (p<0.001 for both). Data on 72 VHR patients (60%) were obtained with follow!up duration of 19.7±5.8 months. No patient achieved the target LDL!C level of less than 1.4 mmol/L. Conclusion. Three!year follow!up of participants in the RENAISSANCE registry shows an enhanced adherence to hypolipidemic therapy. In FH patients the increased risk of new CVE is associated with male sex, hypertension, CHD, family history of CVD and lipoprotein(a) level ≥30 mg/dl

Download Full-text

The effects of preventive counseling followed by remote support via phone on the motivation to change lifestyle in patients with high cardiovascular risk

European Journal of Preventive Cardiology ◽

10.1093/eurjpc/zwab061.316 ◽

2021 ◽

Vol 28 (Supplement_1) ◽

Author(s):

N Pogosova ◽

AI Yusubova ◽

YM Yufereva ◽

OY Sokolova ◽

AV Karpova ◽

...

Keyword(s):

Cardiovascular Risk ◽

Intervention Group ◽

Lifestyle Changes ◽

Control Group ◽

Motivation To Change ◽

High Cardiovascular Risk ◽

Diet Modification ◽

Preventive Counseling ◽

Very High

Abstract Funding Acknowledgements Type of funding sources: None. Background Personal motivation for lifestyle change plays a fundamental role in modifying unhealthy habits. It can be improved, for example, through education. Objectives To assess the effects of preventive counseling with focus on diet modification followed by remote support via telephone on the motivation to change lifestyle in patients (pts) with high cardiovascular risk in a long-term follow-up. Methods This is a prospective randomized controlled study of pts aged 40 to 65 years with high/very high CV risk (≥5% according to the Systematic Coronary Risk Evaluation scale [SCORE]) and any 2 criteria of metabolic syndrome. Pts were randomized into 2 groups in 1:1 ratio. The intervention group received comprehensive preventive counseling with focus on diet modification followed by remote preventive counseling by phone every two weeks for the first 3 months after enrollment (a total of 6 sessions). The control group received usual care in Health centers which also included basic preventive counseling. A specially designed questionnaire was used to evaluate the motivation to change lifestyle at baseline and 12 months. Results A total of 100 pts (women - 80%, aged 59.85 ± 4.47 years) were randomized. At baseline 81% pts had high and 19% - very high CV risk. The groups were well balanced according to demographic and clinical features. At 1 year of follow-up the intervention group experienced significant improvement in motivation for lifestyle changes vs control. The proportion of pts achieving advanced stages of change process was 38% vs. 12% in the control group where 82% of pts only continued to think of lifestyle modification. Conclusion Preventive counseling followed by remote support via phone provided a significant improvement in motivation to change lifestyle. Intervention group Control group P for change from baseline Baseline After 12 months Baseline After 12 months Not ready yet, % 0 0 0 0 <0.05 Often think of lifestyle changes, % 62 46 86 82 Ready to do changes if provided specific advices, % 32 16 12 6 Are in process of successful changes, % 6 38 2 12

Download Full-text

Antihypertensive Efficacy of Fixed Combination of Amlodipine and Ramipril in Patients with Arterial Hypertension and Very High Cardiovascular Risk

Rational Pharmacotherapy in Cardiology ◽

10.20996/1819-6446-2018-14-6-840-845 ◽

2019 ◽

Vol 14 (6) ◽

pp. 840-845

Author(s):

O. Yu. Korennova ◽

S. P. Podolnaya ◽

E. P. Prihodko ◽

E. A. Turusheva ◽

S. N. Starinskaya ◽

...

Keyword(s):

Cardiovascular Risk ◽

Coronary Artery ◽

Fixed Combination ◽

Antihypertensive Drugs ◽

Antihypertensive Efficacy ◽

High Cardiovascular Risk ◽

Hypertensive Patients ◽

Coronary Artery Stenting ◽

History Of ◽

Very High

Aim. To evaluate the antihypertensive efficacy and tolerability of a fixed combination of amlodipine and ramipril in hypertensive patients with very high cardiovascular risk. Material and methods. A retrospective cohort study of real clinical practice of prescribing antihypertensive drugs according to 255 medical records of outpatient hypertensive patients with a history of acute coronary syndrome (ACS) and coronary artery stenting was performed in the first part. An open observational study was performed in the second part. 69 people older than 18 years with a history of ACS and coronary artery stenting, without reaching the target blood pressure (BP) level while using free combinations of antihypertensive drugs and with indications for a fixed combination of ramipril and amlodipine were included into the study. Analysis of self-monitoring of BP, office BP, daily BP monitoring (ABPM) and patients’ adherence to treatment (Morisky-Green test) initially, after 4 and after 12 weeks of taking the fixed combination of ramipril and amlodipine was performed to assess the clinical efficacy of the studied drug. Results. It was found that 42.0% of patients did not follow the recommendations for regular intake of antihypertensive drugs. So, hypertension of all patients regarded as false-refractory, which was the basis for the prescription of the fixed combination of ramipril and amlodipine in accordance with clinical guidelines for the diagnosis and treatment of hypertension. After 4 weeks of therapy, there was significant decrease in office BP with the achievement and preservation of the target level by the 12th week, normalization to the 12th week of day and night BP variability in 54.9% of patients. 78.0% of patients followed medical recommendations for regular administration of antihypertensive drugs, none of the patients had adverse events. Conclusion. The use of fixed combinations of drugs, in particular, amlodipine and ramipril as a part of multicomponent therapy in hypertensive patients with very high cardiovascular risk, led to the achievement of target BP by the 4th week of therapy and stable preservation of antihypertensive effect in 12 weeks of treatment as well as gradual normalization of day and night BP variability in more than half of patients. Fixed combination of ramipril and amlodipine allowed to improve adherence of patients to cardiovascular diseases.

Download Full-text